N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Ryan Mee, CEO of Fulcrum Metals
Zak Mir talks to Ryan Mee, CEO of Fulcrum Metals, in the wake of the Panther Met -
Zak Mir talks to Segun Lawson, President & CEO of Thor Explorations
Zak Mir talks to Segun Lawson, CEO of Thor Explorations. The company provided an -
Zak Mir talks to Mark Routh, CEO of Prospex Energy
Zak Mir talks to Mark Routh, CEO of Prospex Energy, an AIM-quoted investment com -
Transforming Biotech: Insights from Tim McCarthy, CEO of ImmuPharma
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of b